Bavarian Nordic is a vaccine-focused
biotechnology company developing and producing novel vaccines for
the treatment and prevention of life-threatening diseases with a
large unmet medical need.
The company's pipeline targets cancer
and infectious diseases, and includes ten development programs. In
oncology, the company's lead program is PROSTVAC®, a
therapeutic vaccine candidate for advanced prostate cancer that is
the subject of an ongoing pivotal Phase 3 trial and is being
developed under a collaboration agreement with the National Cancer
Institute. In infectious diseases, the company's lead program is
IMVAMUNE®, a third-generation smallpox vaccine candidate that
is being developed and supplied for emergency use to the U.S.
Strategic National Stockpile under a contract with the U.S.
Government.
Bavarian Nordic is listed on NASDAQ OMX
Copenhagen under the symbol BAVA.
